



Drug Candidates for the Treatment of Genitourinary Malignancies

Guest Editors:

Dr. Rui M. Gil da Costa

Dr. Haissa Oliveira Brito

Post-Graduate Programme in
Adult Health, Universidade
Federal do Maranhão, São Luís,
Brazil

Deadline for manuscript
submissions:

closed (15 September 2022)

Message from the Guest Editors

Dear Colleagues,

Genitourinary malignancies include some of the most prevalent types of cancer worldwide, such as prostate, uterine, cervix and bladder cancer, as well as less prevalent lesions, including vulvar, vaginal and penile cancers. The varied etiology and the molecular heterogeneity of genitourinary cancers represent major challenges for cancer therapy.

.....

This Special Issue aims to highlight timely studies of innovative drug candidates for genitourinary cancers and their molecular targets, including pre-clinical and clinical studies, as well as review articles. Translational research studies are particularly welcome. Studies that deal with the molecular heterogeneity of genitourinary cancers and approaches to therapeutically target specific tumor subsets are also of particular interest. Finally, this Special Issue also aims to showcase studies that deal with less-studied cancers with higher incidence in developing countries, such as penile cancer.

Dr. Rui M. Gil da Costa
Dr. Haissa Oliveira Brito
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com